Velox­is wins $1.3B buy­out, and the new own­er plans to fol­low up with new deals

Japan’s Asahi Ka­sei Phar­ma has stepped up with a deal to buy out Copen­hagen-based Velox­is Phar­ma­ceu­ti­cals for $1.3 bil­lion, bag­ging an or­gan re­jec­tion drug in the process.

The deal comes 17 years af­ter Velox­is was found­ed, and the two big share­hold­ers — No­vo Hold­ings and Lund­beck­fond In­vest — have both signed off on the buy­out. The biotech makes an im­muno­sup­pres­sive drug called En­var­sus XR for kid­ney trans­plants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER